CRISPR Therapeutics to Participate in Upcoming Investor Conferences
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
ZUG, Switzerland and BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following investor conferences in June.
瑞士楚格和波士頓，2024年5月29日（GLOBE NEWSWIRE）——專注於爲嚴重疾病開發變革性基因藥物的生物製藥公司CRISPR Therapeutics（納斯達克股票代碼：CRSP）今天宣佈，其高級管理團隊成員計劃於6月參加以下投資者會議。
Jefferies Healthcare Conference
Date: Wednesday, June 5, 2024
Time: 10:00 a.m. ET
傑富瑞醫療會議
日期：2024 年 6 月 5 日，星期三
時間：美國東部時間上午 10:00
Goldman Sach's 45th Annual Global Healthcare Conference
Date: Tuesday, June 11, 2024
Time: 9:20 a.m. ET
高盛第45屆年度全球醫療保健會議
日期：2024 年 6 月 11 日，星期二
時間：美國東部時間上午 9:20
A live webcast will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcasts will be archived on the Company's website for 14 days following the presentation.
將在公司網站 “投資者” 部分的 “活動與演講” 頁面上進行網絡直播，網址爲 https://crisprtx.gcs-web.com/events。網絡直播的重播將在演示結束後的14天內在公司網站上存檔。
About CRISPR Therapeutics
Since its inception over a decade ago, CRISPR Therapeutics has transformed from a research-stage company advancing programs in the field of gene editing, to a company that recently celebrated the historic approval of the first-ever CRISPR-based therapy and has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic in 2018 to investigate the treatment of sickle cell disease or transfusion-dependent beta thalassemia, and beginning in late 2023, CASGEVY (exagamglogene autotemcel) was approved in some countries to treat eligible patients with either of those conditions. The Nobel Prize-winning CRISPR science has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer and Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California, and business offices in London, United Kingdom. To learn more, visit www.crisprtx.com.
關於 CRISPR 治療學
自十多年前成立以來，CRISPR Therapeutics已從一家推進基因編輯領域項目的研究階段公司轉變爲一家最近慶祝了有史以來第一種基於CRISPR的療法獲得歷史性批准的公司，並在包括血紅蛋白病、腫瘤學、再生醫學、心血管、自身免疫和罕見疾病在內的廣泛疾病領域擁有多樣化的候選產品組合。CRISPR Therapeutics於2018年將有史以來第一種經過CRISPR/Cas9基因編輯的療法推向臨床，以研究鐮狀細胞病或輸血依賴性β地中海貧血的治療方法。從2023年底開始，CASGEVY（exagamglogene autotemcel）在一些國家獲准用於治療患有這兩種疾病的符合條件的患者。諾貝爾獎得主CRISPR科學徹底改變了生物醫學研究，是一種經過臨床驗證的強大方法，有可能創造出一類具有潛在變革性的新藥物。爲了加快和擴大其努力，CRISPR Therapeutics已與拜耳和Vertex Pharmicals等領先公司建立了戰略合作伙伴關係。CRISPR Therapeutics AG總部位於瑞士楚格，其全資美國子公司CRISPR Therapeutics, Inc.，研發部門位於馬薩諸塞州波士頓和加利福尼亞州舊金山，業務辦公室位於英國倫敦。要了解更多信息，請訪問 www.crisprtx.com。
Investor Contact:
Susan Kim
+1-617-307-7503
susan.kim@crisprtx.com
投資者聯繫人：
蘇珊·金
+1-617-307-7503
susan.kim@crisprtx.com
Media Contact:
Rachel Eides
+1-617-315-4493
rachel.eides@crisprtx.com
媒體聯繫人：
雷切爾·艾德斯
+1-617-315-4493
rachel.eides@crisprtx.com
Source: CRISPR Therapeutics AG
資料來源：CRISPR 治療股份公司
譯文內容由第三人軟體翻譯。